These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 21607923)
21. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma. Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581 [TBL] [Abstract][Full Text] [Related]
22. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123 [TBL] [Abstract][Full Text] [Related]
23. [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma]. Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477 [TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling of primary cutaneous melanoma. Winnepenninckx V; Van den Oord JJ Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873 [TBL] [Abstract][Full Text] [Related]
25. [Serum markers for melanoma]. Ugurel S Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726 [TBL] [Abstract][Full Text] [Related]
26. Proteomic analysis of gliomas. Whittle IR; Short DM; Deighton RF; Kerr LE; Smith C; McCulloch J Br J Neurosurg; 2007 Dec; 21(6):576-82. PubMed ID: 18071984 [TBL] [Abstract][Full Text] [Related]
28. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. Liu YF; Xiao ZQ; Li MX; Li MY; Zhang PF; Li C; Li F; Chen YH; Yi H; Yao HX; Chen ZC J Pathol; 2009 Jan; 217(1):54-64. PubMed ID: 18798225 [TBL] [Abstract][Full Text] [Related]
29. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673 [TBL] [Abstract][Full Text] [Related]
30. Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR. Hilari JM; Mangas C; Xi L; Paradelo C; Ferrándiz C; Hughes SJ; Yueh C; Altomare I; Gooding WE; Godfrey TE Ann Surg Oncol; 2009 Jan; 16(1):177-85. PubMed ID: 18982394 [TBL] [Abstract][Full Text] [Related]
31. Circulating serologic and molecular biomarkers in malignant melanoma. Palmer SR; Erickson LA; Ichetovkin I; Knauer DJ; Markovic SN Mayo Clin Proc; 2011 Oct; 86(10):981-90. PubMed ID: 21964175 [TBL] [Abstract][Full Text] [Related]
32. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J Oncology; 2003; 64(4):374-9. PubMed ID: 12759535 [TBL] [Abstract][Full Text] [Related]
33. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515 [TBL] [Abstract][Full Text] [Related]
34. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers]. Solassol J; Marin P; Maudelonde T; Mangé A Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265 [TBL] [Abstract][Full Text] [Related]
35. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
36. Proteomic technologies and their application to pancreatic cancer. Vimalachandran D; Costello E Expert Rev Proteomics; 2004 Dec; 1(4):493-501. PubMed ID: 15966844 [TBL] [Abstract][Full Text] [Related]
38. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759 [TBL] [Abstract][Full Text] [Related]
39. Circulating miRNA expression analysis reveals new potential biomarkers for human cutaneous melanoma staging. Sánchez-Sendra B; García-Giménez JL; González-Muñoz JF; Navarro L; Murgui A; Terrádez L; Pinazo I; Martin JM; Monteagudo C J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e126-e129. PubMed ID: 31710393 [No Abstract] [Full Text] [Related]
40. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]